![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Revises Its Policy on Multi-Analyte COVID-19 EUAs
FDA Revises Its Policy on Multi-Analyte COVID-19 EUAs
![FDA Logo device green](https://www.fdanews.com/ext/resources/test/Device_Images/fda-logo.gif?t=1614205361&width=430)
The FDA has updated its policy on COVID-19 testing, clarifying that manufacturers of multi-analyte respiratory panels which include SARS-CoV-2 are now eligible for Emergency Use Authorization (EUA).
The agency noted that multi-analyte panels are useful when multiple respiratory pathogens are circulating at the same time, as is expected with the upcoming flu season.
When determining whether to issue an EUA for a multi-analyte respiratory panel that includes SARS-CoV-2, the agency said it considers the clearance or approval status of diagnostics for the other analytes on the panel.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct